Pharmaceuticals News and Research

RSS

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.

22 Nov 2010

Pfizer subsidiary extends tender offer for King acquisition

Pfizer Inc. today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

22 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

BioNeutral signs 'Stand Still' agreement with DFB

BioNeutral Group, Inc., a specialty technology-based life science company, today announced it has signed a "Stand Still" agreement with a leading pharmaceutical company, DFB Pharmaceuticals, Inc. (DFB).

From Evident Corporation - Life Sciences 22 Nov 2010

Bacterin secures $8 million financing from WTI

Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that it has secured an asset based lending facility of up to $8.0 million from Western Technology Investment, and has received approximately $980,000 through the exercise of warrants for a total of approximately $9 million potentially available for the Company's use.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

NASDAQ issues second letter to A.P. Pharma

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.

22 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

ImmunGene awarded $244,479 therapeutic discovery project grant under PPACA 2010

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that it has received a $244,479 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to the development of ImmunGene's technology which is based on antibody-cytokine fusions that have demonstrated targeted toxicity and added tumor benefits.

22 Nov 2010

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.

22 Nov 2010

PointCross releases SDIS technology to BioPharma industry

PointCross announces the release of its Study Data Integration and Search (SDIS) technology and associated services to the BioPharma industry for private use with legacy and current studies.

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Best Practices study: Mock review helps effective approach for preparing team for NDA advisory committee meeting

Pharmaceutical companies with good track records of approvals and first approvals are characterized not only by strong science but also strong working relationships with the FDA. Regulatory Affairs is the function that oversees and guides interactions with the FDA it's a job that comes with a plethora of responsibilities related to New Drug Applications (NDA).

20 Nov 2010

Scientific workshop to focus on advanced analytical techniques

Almac, in association with the Royal Society of Chemistry, hosted a scientific workshop focusing on advanced analytical techniques used to optimise, monitor and control solid state properties during the development of new medicines.

20 Nov 2010

Bohai first quarter net revenues increase 22% to $17.0 million

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the availability of the transcript for its fiscal first quarter ended September 30, 2010 earnings conference call, held on November 15th.

20 Nov 2010

Researchers to discuss latest advances in Alzheimer's research

Today, America's biopharmaceutical research companies highlighted the 98 new medicines in the pipeline for Alzheimer's disease and other dementias, either in clinical trials or awaiting FDA review.

20 Nov 2010

Novartis gender discrimination case settlement final hearing on November 19

The final hearing for approval of the class settlement in the long-running class action gender discrimination case brought by female sales representatives at Novartis Pharmaceutical Corporation is set for Friday, November 19th at 10 a.m. in the courtroom of Judge Colleen McMahon of United States District Court for the Southern District of New York in Manhattan.

20 Nov 2010

Pharmaceuticals News and Research

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

Pfizer subsidiary extends tender offer for King acquisition

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

BioNeutral signs 'Stand Still' agreement with DFB

Bacterin secures $8 million financing from WTI

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

NASDAQ issues second letter to A.P. Pharma

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

ImmunGene awarded $244,479 therapeutic discovery project grant under PPACA 2010

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

PointCross releases SDIS technology to BioPharma industry

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Best Practices study: Mock review helps effective approach for preparing team for NDA advisory committee meeting

Scientific workshop to focus on advanced analytical techniques

Bohai first quarter net revenues increase 22% to $17.0 million

Researchers to discuss latest advances in Alzheimer's research

Novartis gender discrimination case settlement final hearing on November 19

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence